Home › Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
 

Keywords :   


Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine

2014-11-24 13:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & AMES, IA Clinical Development, Manufacturing Expertise, and Scale Critical to Success WHITEHOUSE STATION, N.J. & AMES, IA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLinks investigational rVSV-EBOV (Ebola) vaccine candidate. Language: English Contact: Merck Media Contacts:Pam Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:NewLink GeneticsJack Henneman, 515-598-2561orMerckJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more

Tags: enter agreement collaboration licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
More »